Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients (MAGMA)
Non-small Cell Lung Cancer

About this trial
This is an interventional diagnostic trial for Non-small Cell Lung Cancer focused on measuring PET/CT, MMR-PET/CT, Macrophage PET/CT, CD206
Eligibility Criteria
Inclusion Criteria: Patients who have given informed consent Patients at least 18 years old Patient with local, locally advanced or metastatic disease of lung cancer, who is planned for resection or surgical biopsy of at least one lesion. In order to minimise partial volume effect, the diameter of the tumour to be resected or biopsied should be ≥ 10 mm in short axis for invaded adenopathies and ≥ 10 mm in long axis for all other types of lesions Patients who participated already in this study can be included if the subject meets all of the inclusion and none of the exclusion criteria at time of second inclusion. Exclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status 3 or higher Pregnant patients Breast feeding patients Patients with any serious active infection Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test radiopharmaceutical Patients who are unlikely to cooperate with the requirements of the study Patients who are unwilling and/or unable to give informed consent Patients at increased risk of death from a pre-existing concurrent illness
Sites / Locations
- Universitair Ziekenhuis BrusselRecruiting
Arms of the Study
Arm 1
Other
Patients diagnosed with non-small cell lung cancer (NSCLC), planned for standard-of-care surgery